SK bioscience files trial application for RSV antibody candidate

South Korean biotechnology company SK bioscience has filed an application to begin clinical trials for its investigational antibody designed to treat respiratory syncytial virus (RSV).

The move follows preclinical research and regulatory preparations to assess the safety and efficacy of the candidate, which targets RSV, a common respiratory pathogen that can lead to severe infections, particularly in infants and older adults.

SK bioscience, a subsidiary of SK Group, did not disclose a specific timeline for the trial initiation or details about the antibody’s mechanism in the announcement. The company stated that further updates would be provided pending regulatory review and approval.

RSV infections result in significant global healthcare burdens, with limited treatment options currently available. The development of monoclonal antibodies and vaccines has become a priority for pharmaceutical firms amid rising cases and seasonal outbreaks.

The trial application submission aligns with broader industry efforts to expand therapeutic options for RSV, which has seen increased attention in recent years due to its impact on vulnerable populations.